BiBBInstruments receives additional orders for EndoDrill[®] GI from the U.S.

BiBBInstruments reported incremental U.S. orders from distribution partner TaeWoong Medical USA totaling $31,840 (SEK 300,000) in Q4 as part of a targeted U.S. launch started in the fall; management said the Q4 order value exceeds Q3 sales by more than 170%. TaeWoong is working to establish routine use at several larger reference hospitals to form the basis for a wider U.S. rollout in 2026, and BiBB is holding discussions with potential European partners with a view to market entry there in 2026. EndoDrill® GI — a powered EUS biopsy system with FDA 510(k) clearance and CE marking and already in clinical use — is showing early commercial traction, but the current order size is small and broader revenue upside will depend on successful hospital adoption and distributor expansion next year.

Analysis

BiBBInstruments reported additional U.S. orders from distribution partner TaeWoong Medical USA totaling $31,840 (SEK 300,000) during Q4, part of a targeted U.S. launch that began in fall 2025; management notes Q4 order value exceeds Q3 sales by more than 170%. TaeWoong is prioritizing establishment of routine use at a number of larger reference hospitals to form the basis for a broader nationwide U.S. rollout in 2026, and parallel discussions are underway with prospective European distributors for a 2026 market introduction.

EndoDrill® GI is the company’s lead product and is positioned distinctively: it is the world’s first powered EUS biopsy instrument with FDA 510(k) clearance in 2023 and CE marking in 2024, currently in clinical use in both regions, and designed to retrieve intact tissue cores enabling molecular analysis. The combination of regulatory clearance and early clinical deployment reduces regulatory timing risk but leaves commercial execution as the principal hurdle.

The announcement signals early commercial traction but the absolute order value remains modest and commercially immaterial at this stage; sustainable revenue depends on repeat orders, reference-hospital conversions and signed distributor agreements in the U.S. and Europe. Key near-term indicators to monitor are sequential order cadence, hospital adoption reports from TaeWoong, and confirmation of wider distribution contracts ahead of the planned 2026 rollouts.

Key Decisions for Investors

• Treat the release as constructive proof-of-concept but commercially small; maintain or initiate only a modest, speculative position until sustained sequential order growth is demonstrated
• Monitor KPIs closely: quarterly order cadence, number of reference hospitals adopting EndoDrill, and formal U.S. nationwide rollout timetable or signed European distribution agreements; consider adding incrementally if momentum persists (comparable to Q4’s >170% improvement over Q3)
• Prioritize updates from TaeWoong and any European partner announcements as primary catalysts and set clear exit/trim rules if order momentum or distributor commitments do not materialize by mid-2026